The evaluation on the therapeutic effect of intravenous metoprolol on patients with rapid atrial fibrillation

Objective:To observe the therapeutic effect and safety of intravenous metoprolol on atrial fibrillation. Method:Forty-two patients were divided into metoprolol group and cedilanid group randomly. The twenty-one patients in metoprolol group were injected metoprolol intravenously at doses of 5～15 mg. The twenty-one patients in cedilanid group were injected intravenously at doses of 0.4～0.8 mg. The heart rate and blood pressure before the injection and 40 min, 60 min and 120 min after the injection were observed respectively. Result:1. There were twelve cases and eight cases respectively in two groups whose heart rate decreased to less than 100 bpm. There were no significant differences between the two groups ( P 0.05). 2. The average time in metoprolol group and cedilanid group whose heart rate decreased to less than 100 bpm is (18.33±12.31) min and (65.00±35.05) min respectively. There was significant difference between two groups ( P 0.01). 3. The average time of becoming effective of intravenous metoprolol is (14.00±9.95) min, while that of becoming effective of intravenous cedilanid is (62.50±41.66) min, There was significant difference between two groups ( P 0.01). 4. The total effective rate of intravenous metoprolol and cedilanid is 85.71% and 47.62% respectively, There was significant difference between two groups ( P 0.05). 5. The most frequent adverse effect of metoprolol observed during the study was hypotension. No cardiac insufficiency and severe arrhythmias occurred. Conclusion:It is effective and safe that administering intravenous metoprolol to patients with rapid atrial fibrillation. And intravenous metoprplol has been another credible way of treating rapid atrial fibrillation in emergency department.